Skip to main content
PLOS Genetics logoLink to PLOS Genetics
. 2020 Apr 9;16(4):e1008555. doi: 10.1371/journal.pgen.1008555

XPF-ERCC1 protects liver, kidney and blood homeostasis outside the canonical excision repair pathways

Lee Mulderrig 1, Juan I Garaycoechea 2,*
Editor: Nancy Maizels3
PMCID: PMC7144963  PMID: 32271760

Abstract

Loss of the XPF-ERCC1 endonuclease causes a dramatic phenotype that results in progeroid features associated with liver, kidney and bone marrow dysfunction. As this nuclease is involved in multiple DNA repair transactions, it is plausible that this severe phenotype results from the simultaneous inactivation of both branches of nucleotide excision repair (GG- and TC-NER) and Fanconi anaemia (FA) inter-strand crosslink (ICL) repair. Here we use genetics in human cells and mice to investigate the interaction between the canonical NER and ICL repair pathways and, subsequently, how their joint inactivation phenotypically overlaps with XPF-ERCC1 deficiency. We find that cells lacking TC-NER are sensitive to crosslinking agents and that there is a genetic interaction between NER and FA in the repair of certain endogenous crosslinking agents. However, joint inactivation of GG-NER, TC-NER and FA crosslink repair cannot account for the hypersensitivity of XPF-deficient cells to classical crosslinking agents nor is it sufficient to explain the extreme phenotype of Ercc1-/- mice. These analyses indicate that XPF-ERCC1 has important functions outside of its central role in NER and FA crosslink repair which are required to prevent endogenous DNA damage. Failure to resolve such damage leads to loss of tissue homeostasis in mice and humans.

Author summary

The integrity of DNA is essential for life so even the most primitive life forms have evolved a DNA repair ‘toolkit’ to detect and fix different types of DNA damage. XPF-ERCC1 is an enzyme that can cut DNA and a key player in many of these DNA repair transactions. Consistent with this, inactivating mutations of XPF-ERCC1 in humans and mice lead to a dramatic premature ageing phenotype associated with liver, kidney and bone marrow dysfunction. Here, we ask which of the many functions of XPF-ERCC1 are required to protect tissues from endogenous DNA damage. To do this, we generated cells and mice lacking two of the best characterised functions of XPF-ERCC1: nucleotide excision repair and inter-strand crosslink repair. Surprisingly, neither the cells nor mice lacking these two repair pathways behave like the XPF-ERCC1 mutants, in fact the mice are remarkable in their lack of phenotype. Our work suggests that there are functions of XPF-ERCC1 outside of the canonical repair pathways which are important for DNA repair and the homeostasis of multiple organs.

Introduction

The integrity of DNA is essential for life so even the most primitive life forms have evolved a DNA repair ‘toolkit’ to detect and remove DNA damage. This damage can range from simple base modifications to breaks in the sugar phosphate backbone, and so specialized pathways exist that are dedicated to fixing specific types of lesions [1].

In mammals, the structure-specific endonuclease XPF-ERCC1 is a key enzyme involved in several of these DNA repair pathways. It is a key component of both branches of nucleotide excision repair (NER), where it removes bulky DNA lesions such as those caused by UV light. Global-genome (GG)-NER senses distortions of the DNA helix whereas transcription-coupled (TC)-NER recognises bulky lesions that lead to stalling of the RNA polymerase. These two branches converge on common NER factors, including XPA, which recruits XPF-ERCC1 to sites of damage. XPF-ERCC1 along with a second endonuclease, XPG, make incisions flanking the DNA adduct prior to filling in of the gap [2].

XPF-ERCC1 is also essential for the repair of inter-strand crosslinks (ICLs) [3,4]. ICLs covalently bind the opposing strands of the DNA helix, blocking both the transcription and replication machineries. ICL-inducing agents like mitomycin C (MMC) and cisplatin are particularly toxic to highly proliferative cells and they are therefore widely utilized in chemotherapy. However, endogenous metabolites like simple aldehydes are also thought to crosslink DNA in vivo [57]. The majority of ICL repair is thought to occur during replication and it is regulated by a set of proteins defective in the human disease Fanconi anaemia (FA). The FA proteins sense the stalling of the replication fork upon its arrival at the crosslink and monoubiquitinate FANCD2, an event which is absolutely required for incisions at either side of the adduct [8]. This ‘unhooking’ step is dependent on XPF-ERCC1 and is followed by trans-lesion synthesis (TLS) and homologous recombination (HR) steps to resolve the remaining DNA double-strand break (DSB) [3,4]. Finally, orthologues of XPF-ERCC1 in yeast, flies and plants are involved in the repair of DSBs by HR, and a similar role has been proposed for XPF-ERCC1 in mammals [9].

In humans, defects in GG-NER cause Xeroderma pigmentosum (XP), characterised by photosensitivity and a 10.000-fold increase in the risk of skin cancer [10]. Mutations in TC-NER cause Cockayne syndrome (CS), characterised by photosensitivity, severe growth failure, cachexia, short life span and progressive neurodegeneration, but no cancer predisposition [11]. Children with FA, that results from a defect in ICL repair, suffer from developmental abnormalities, bone marrow failure and have increased risk of cancer [12]. Consistent with the fact that XPF-ERCC1 is involved in multiple DNA repair pathways, inactivating mutations in humans can lead to aspects of XP, CS or FA, and in extreme instances, a combination of all three phenotypes [1315]. These phenotypes are mirrored in mice, with Ercc1-/- (or Xpf-/-) mice suffering from multisystem degenerative features, severe growth deficits and short lifespan [1618]. The liver of Ercc1-/- mice is prominently affected, with hepatocellular karyomegaly which correlates with impaired liver function [16,17]. Rescue of liver failure with a liver-specific Ercc1 transgene extended the life span of these mice and revealed renal dysfunction coupled with abnormal renal histopathology [19]. Another prominent phenotype in Ercc1-/- mice is the development of neurodegeneration, trembling and ataxia, together with kyphosis and muscle wastage, signs of premature ageing [13]. Ercc1-/- mice also show a haematopoietic defect in line with their lack of ICL repair [20,21]. In contrast, Xpa-/- mice are indistinguishable from wild type mice unless treated with carcinogens [22] and FA-deficient mice (like Fanca-/-) are sterile and develop a mild haematopoietic defect [23,24]

Given the stark contrast between the phenotypes of Ercc1-/-, Xpa-/- and Fanca-/- mice, we wanted to determine which aspects of XPF-ERCC1 deficiency result from the joint inactivation of NER and ICL repair, and whether these two pathways act to repair a common lesion in vivo. In E. coli, NER is essential for ICL repair: the endonuclease UvrA2BC makes incisions at either side of the crosslink on the same DNA strand, leaving a gap and a large monoadduct on the opposite strand [25,26]. The gap serves as a substrate for HR or can be bypassed by TLS in a recA- mutant. This pathway is essentially conserved in yeast, where NER factors are absolutely required to unhook the crosslink, allowing subsequent HR or TLS [27,28]. In mammals, both NER branches have been implicated in replication-independent ICL repair, with GG-NER being required for ICL removal during G1 phase of the cell cycle and TC-NER factors being required for transcription-coupled ICL repair [29,30]. Therefore, NER might provide an alternative ICL repair pathway, especially in tissues with low proliferative rates, and cannot therefore rely on replication-coupled repair of crosslinks.

Here we use somatic cell lines and mouse genetics to test the hypothesis that the NER and FA pathways are redundant for ICL repair, shedding light on the physiological relevance of the various functions of the XPF-ERCC1 nuclease. We show that although the TC-NER factors XPA and CSB are involved in cellular protection against ICLs, the cellular sensitivity of XPF-deficient cells to crosslinking agents and the severe phenotype of the Ercc1-/- mice cannot be explained by joint inactivation of NER and FA repair. Our work suggests that there are functions of XPF-ERCC1 outside of the canonical NER and FA repair pathways which are important for ICL repair and the homeostasis of multiple organs.

Results

XPF-ERCC1 is required for normal tissue homeostasis in the liver, kidney and blood

To begin to address the genetic relationship between NER and ICL repair, we first wanted to establish and compare the phenotype of mice lacking NER, the FA pathway or the nuclease XPF-ERCC1. To this end, we used mice lacking FANCA, a component of the FA core complex required for the ubiquitination of FANCD2; XPA, a critical component of both the GG and TC branches of NER; and ERCC1, required for both branches of NER and ICL repair. Disruption of Ercc1 in an inbred C57BL/6 background yields very few Ercc1-/- mice, which die soon after birth [31]. However, the severity of the phenotype can be alleviated in an C57BL/6 x 129S6/Sv F1 mixed genetic background and mice die around 12–13 weeks (S1 Fig) [17], allowing for a side-by-side comparison of liver, kidney and haemopoietic function across genotypes.

We assessed liver function through biochemical analysis of blood serum and found, in agreement with previous work [16], that Ercc1-/- mice have raised levels of alanine transaminase (ALT), a marker of liver damage; whereas the Xpa-/- mice and the Fanca-/- mice had normal levels (Fig 1A). Histologically, only Ercc1-/- mice displayed karyomegaly in the liver, which is thought to be a consequence of excessive DNA damage (Fig 1A). We confirmed that renal function was also affected [19], as shown by increased serum creatinine levels and signs of sclerotic glomeruli in the kidney in Ercc1-/- mice, but not in Xpa-/- or Fanca-/- mice (Fig 1B).

Fig 1. The nuclease XPF-ERCC1 protects liver, kidney and blood homeostasis.

Fig 1

a) Left: serum levels of alanine transaminase (ALT). Right: haematoxylin and eosin (H&E) staining of liver sections (X200, inset X400). b) Left: serum levels of creatinine. Right: H&E staining of kidney sections (X200). c) Left: quantification of stem and progenitor cells (lineage- c-Kit+ Sca-1+, LKS) assessed by flow cytometry. Right: representative flow cytometry profiles of 150.000 lineage- cells. d) Left: quantification of haematopoietic stem cells (lineage- c-Kit+ Sca-1+ CD48-CD150+, HSC) assessed by flow cytometry. Right: flow cytometry profiles of LKS cells from c). In a-d, mice were 8–12 weeks old, C57BL/6 x 129S6/Sv F1 background, n = 13, 9, 11 and 4, error bars represent s.e.m., P: two-tailed Mann-Whitney test). e) Scheme for the generation of E13.5 embryos for the quantification of HSCs in the foetal liver. f) Quantification of LKS cells by flow cytometry in E13.5 foetal liver. g) Quantification of HSCs by flow cytometry in E13.5 foetal liver. In f-g, pups were E13.5 in a C57BL/6 background, n = 56, 24, 15 and 13, error bars represent s.e.m., P: two-tailed Mann-Whitney test.

Although both Xpa-/- and Fanca-/- mice have very mild phenotypes, it is well documented that FA pathway-deficient mice have a reduced number of haematopoietic stem cells (HSCs) [32,33]. Whilst young Xpa-/- mice do not have an overt HSC defect, it has been reported that the haematopoietic progenitor pool is reduced in 1-year old Xpa-/- mice [20]. Ercc1-/- mice have been shown to have a severe HSC defect, though this is thought to be due to loss of the FA pathway [20]. We therefore set out to directly compare the haematopoietic defect between Xpa-/-, Fanca-/- and Ercc1-/- mice. Firstly, we found that young Xpa-/- mice had comparable frequencies of progenitor cells (defined as lineage- c-Kit+ Sca-1+ (LKS), Fig 1C) and HSCs (LKS CD48- CD150+, Fig 1D) when compared to wild type littermates. In contrast, both Ercc1-/- and Fanca-/- mice had a significant reduction both in the frequency of LKS cells and HSCs when compared to wild type or Xpa-/- controls (Fig 1C and 1D). Surprisingly, the magnitude of the HSC defect observed in Ercc1-/- mice was significantly greater than that observed in Fanca-/- mice (Fig 1D, 11.8-fold compared to 1.8-fold).

To exclude the possibility that the more severe HSC defect in Ercc1-/- mice was being compounded by liver and kidney failure, we next quantified HSCs in embryos. The haematopoietic defect in FA-deficient mice begins in utero around day E12.5-E14.5 and should precede liver and kidney dysfunction in Ercc1-/- mice [34,35]. Therefore, we set up timed matings to generate embryos at E13.5 and quantified the frequency of progenitors and HSC in the foetal liver by flow cytometry (Fig 1E). Here we also see that HSC loss is significantly reduced in the Ercc1-/- mice when compared to Fanca-/- mice (Fig 1G and 1F).

Therefore, lack of ERCC1 not only affects organs that are unperturbed in Fanca-/- mice and Xpa-/- mice, but also leads to a more severe contraction in the HSC pool, which is thought to be affected by a deficiency in ICL repair. These data suggest that ERCC1 deficiency removes not only the dominant FA ICL-repair pathway, but also an additional pathway of HSC protection.

Cells deficient in TC-NER are hypersensitive to crosslinking agents

To shed light on whether the phenotype observed in Ercc1-/- mice could be due to simultaneous inactivation of both ICL and NER pathways we turned to the haploid somatic cell line HAP1. We used CRISPR/Cas9 to generate a panel of isogenic knock out cell lines for different components of the NER pathway: XPC, that senses helix distortions and initiates GG-NER; CSB, that signals the stalling of the RNA polymerase and triggers TC-NER; XPA, a scaffold protein required by both branches of NER; and XPF, the endonuclease that cleaves DNA on the 5’ side of the lesion. The knock out lines were validated by Sanger sequencing (S2A Fig), Western blot (Fig 2A) and hypersensitivity to UV (Fig 2B). We found that haploid XPF- cells diploidised spontaneously, so all survival experiments were carried out with diploid lines. We exposed our cell lines to the ICL-inducing agents cisplatin and MMC. In agreement with its documented role in crosslink repair, XPF-/- cells were extremely sensitive to both agents (Fig 2C and 2D). However, XPA-/- and CSB-/- cells were also mildly sensitive to these agents, but XPC-/- cells were indistinguishable from the parental wild type cells. As XPA and CSB both operate in the TC branch of NER, this suggests a role for TC-NER, but not GG-NER, in maintaining cellular resistance to crosslinking agents.

Fig 2. TC-NER confers protection against ICL-inducing agents.

Fig 2

a) Western blots showing lack of NER proteins in HAP1 knock out lines. See S2 Fig for more details. b) Survival of HAP1 cells in response to UV light. c) Survival of HAP1 cells in response to mitomycin C (MMC). d) Survival of HAP1 cells in response to cisplatin. In b-d, each data point represents the mean of at least two independent experiments, each carried out in duplicate, error bars represent s.e.m..

NER and the FA pathway cooperate to repair formaldehyde lesions

Next, we wanted to test whether NER and the FA pathway cooperate to protect against ICLs. To do this, we inactivated FA repair in wild type and XPA-/-cells, using a targeting construct to introduce isogenic disruptions in the FANCL locus (S2B Fig). FANCL is the E3 ubiquitin ligase responsible for FANCD2 monoubiquitination, which is an essential step in ICL repair [8]. We validated the disruption of the FANCL locus by long-range PCR (S2C Fig) and detected loss of FANCD2 ubiquitination by western blot (Fig 3B). We then quantified the survival of these cells in response to crosslinking agents.

Fig 3. NER and the FA pathway cooperate to protect cells from formaldehyde, an endogenous crosslinking agent.

Fig 3

a) Scheme for the isogenic disruption of the FANCL locus in wild type or XPA- HAP1 cells. See S2 Fig for more details. b) Western blots showing lack of FANCD2 monoubiquitination and XPA protein in HAP1 knock out lines. c-h) Survival of HAP1 cells in response to mitomycin C (MMC), cisplatin, UV, irradiation, acetaldehyde and formaldehyde. In c-h, each data point represents the mean of at least two independent experiments, each carried out in duplicate, error bars represent s.e.m..

FANCL-/- and XPF-/- lines, both deficient in FA DNA repair, were hypersensitive to the ICL-inducing agents MMC and cisplatin (Fig 3C and 3D). However, XPF-/- cells were far more sensitive than FA-deficient cells. We found that XPA-/-FANCL-/- cells were no more sensitive than FANCL-/- cells to MMC, but loss of XPA resulted in additive sensitivity to cisplatin (Fig 3C and 3D). This increased sensitivity could be explained by the fact that cisplatin readily generates intrastrand crosslinks (i.e. crosslinking of adjacent bases on the same DNA strand), lesions commonly removed by NER [36]. However, in neither case, joint inactivation of NER and FA repair was sufficient to account for the hypersensitivity of XPF-/- cells. We found that XPF-/- and XPA-/-FANCL-/- cells were equally sensitive to other sources of DNA damage, like UV light and ionizing radiation, suggesting that the extreme sensitivity of XPF-/- was specific to ICL-causing agents (Fig 3E and 3F). These results highlight that the XPF-ERCC1 nuclease plays a critical role in ICL repair, perhaps being involved in alternative repair routes, which are not NER.

Whilst cisplatin or MMC are of significant clinical relevance, we have recently found that reactive aldehydes, by-products of cellular metabolism, could be an important source of endogenous DNA crosslinks [5,7]. These reactive aldehydes may be generated as by-products of metabolism (e.g. 1-carbon metabolism, inflammatory responses), as well as environmental or dietary sources. We therefore exposed XPA-/-FANCL-/- and control cell lines to the simple aldehydes acetaldehyde and formaldehyde (Fig 3G and 3H). Lack of NER did not further sensitise FANCL-/- cells to acetaldehyde. In contrast, XPA-/-FANCL-/- cells were more sensitive to formaldehyde than either single mutant, with comparable sensitivity to XPF-/- cells. Although closely related, the reactivity and types of lesions caused by these aldehydes differ [37]. The additional hypersensitivity to formaldehyde may be due to this compound causing a different spectra of DNA lesions, which might include base adducts, DNA inter- and intrastrand crosslinks as well as DNA-protein crosslinks [38]. However, NER and FA repair are both required to maintain cellular resistance to the same endogenous genotoxin—formaldehyde. Although we have exposed cells to exogenous formaldehyde in vitro, it is also clear that cells within organisms are exposed to reactive aldehydes without exogenous exposure. Therefore, NER and FA repair constitute alternative pathways to repair lesions caused by this endogenous compound and both rely upon the activity of XPF-ERCC1.

TC-NER and the FA pathway preserve normal development

We set out to generate mice deficient in both NER and the FA DNA repair pathway to investigate the physiological relevance of this observation. To this end, we first crossed Xpa+/- and Fanca+/- mice in a pure C57BL/6 background. To generate double mutant mice, we exploited the fact that NER-deficient mice are fertile and set up Xpa-/- Fanca+/- x Xpa-/- Fanca+/- crosses, which would generate the highest frequency of double mutants while minimizing the amount of breeding required. We then compared the number of Fanca-/- pups genotyped at 2–3 weeks between the NER proficient and deficient crosses (Fig 4A and 4B). We found Xpa-/-Fanca-/- pups to be underrepresented compared to Fanca-/- pups (1.5% instead of 13.3%, P < 0.0001) and born as rarely as Ercc1-/- pups in a C57BL/6 background (S1 Fig, 1.5% vs 1.9%, P = 0.67). This indicated a genetic interaction between NER and ICL repair to preserve mouse development. To investigate the significant reduction in the frequency of double mutants, we performed timed matings between Fanca+/- or Xpa-/-Fanca+/- crosses and sacrificed pregnant females at day E13.5. Xpa-/-Fanca-/- pups were found at a frequency of 11.4% (from n = 35, vs 29% Fanca-/- pups n = 72, P = 0.04) and were grossly underdeveloped compared to controls (Fig 4C).

Fig 4. TC-NER and the FA pathway cooperate to ensure normal mouse development.

Fig 4

a) Fanca+/- crosses in a C57BL/6 background showing that Fanca-/- mice are genotyped at sub-Mendelian ratios 2–3 weeks after birth (13.3% instead of the expected 25%, P: Fisher’s exact test compared to expected numbers. b) Xpa-/-Fanca+/- crosses for the generation of double mutant mice in a C57BL/6 background c) Examination of E13.5 embryos generated from Fanca+/- or Xpa-/-Fanca+/- crosses in a C57BL/6 background. d) Xpc-/- Fanca+/- crosses for the generation of double mutant mice in a C57BL/6 background. e) Csbm/m Fanca+/- crosses for the generation of double mutant mice in a C57BL/6 background. In a, b, d, and e, pups were genotyped 2–3 weeks after birth. In b, d, and e P: Fisher’s exact test, compared to numbers from Fanca+/- crosses.

Therefore, NER and ICL repair genetically interact to preserve mouse development in a C57BL/6 background. To further dissect this observation, we crossed Fanca+/- mice with mice only lacking GG-NER (Xpc-/-) or TC-NER (Csbm/m). Xpc-/- mice are sensitive to UV light exposure but have otherwise near-normal lifespans and no overt phenotypes [39]. Csbm/m mice are also sensitive to UV light and show retinal degeneration, as well as mild growth retardation and neurodegenerative changes, an extremely mild version of human CS [40]. We found that Xpc-/- Fanca-/- pups were born at the same frequency as Fanca-/- pups (11.5% vs 13.3%, P = 0.5616) (Fig 4D). In contrast, Csbm/m Fanca-/- pups were underrepresented compared to Fanca-/- pups (5.5% vs 13.3%, P = 0.0020) (Fig 4E). When put together, these results show that the FA pathway genetically interacts with components of TC-NER pathway, but not GG-NER, to preserve development. These results agree with the observation that both the FA pathway and TC-NER are required protect cells from crosslinking agents in vitro (Fig 2C and 2D). In sum, TC-NER and FA repair are jointly required to preserve normal mouse development in a C57BL/6 background.

Simultaneous inactivation of NER and ICL repair does not recapitulate XPF-ERCC1 deficiency

The strong genetic interaction between TC-NER and FA repair in utero prompted us to ask if joint inactivation of these repair pathways might explain some aspects of the Ercc1-/- phenotype. Ercc1-/- mice on a C57BL/6 background are born at an extremely low ratio but a C57BL/6 x 129S6/Sv F1 hybrid background circumvents this lethality and allows the study of the role of XPF-ERCC1 in postnatal life (S1 Fig) [17]. In complete contrast to the very mild phenotypes of Csbm/m, Xpa-/- and Fanca-/- mice, Ercc1-/- mice suffer from multisystem degenerative features, severe growth deficits and short lifespan. In order to investigate if some aspects of this phenotype are due to joint inactivation of NER and FA repair, we sought to generate Xpa-/- Fanca-/- mice on an C57BL/6 x 129S6/Sv F1 hybrid background, and compare this to the phenotype of Ercc1-/- C57BL/6 x 129S6/Sv F1 mice. Indeed, the embryonic lethality of double mutants in the C57BL/6 background (Fig 4B) was completely rescued on the F1 genetic background (S3A Fig). The C57BL/6 congenic background is known to potentiate the phenotype of DNA repair-deficient mice [4143].

Postnatal growth is severely retarded in Ercc1-/- mice. However, the weight of both Xpa-/- Fanca-/- and Csbm/m Fanca-/- was undistinguishable from Fanca-/- mice at 8 weeks of age (S3B Fig). We then set out to assess liver and kidney function in these double mutants, as these two tissues lose homeostasis accompanied by morphological changes in Ercc1-/- mice. The hepatocytes of these mice display polyploidy and this is associated with compromised liver function. We observed no gross histological abnormalities in the liver of Xpa-/-Fanca-/- or Csbm/mFanca-/- mutants. Whilst we could detect polyploid nuclei in the liver of Ercc1-/- mice, we detected normal DNA content in Xpa-/-Fanca-/- and Csbm/mFanca-/- livers (Fig 5A and 5C, S3C Fig). Liver function was also normal as judged by the concentration of albumin and liver enzymes in blood serum (Fig 5D). We then focused our attention on the kidney phenotype, as Ercc1-/- mice show abnormal renal histopathology (glomerulosclerosis and protein casts) and renal dysfunction (significantly elevated serum creatinine and urea) [19]. However, we did not detect any of these changes in mice lacking both NER and the FA pathway (Fig 5E and 5F, S3 Fig).

Fig 5. Joint inactivation of NER and FA crosslink repair does not phenocopy XPF-ERCC1 deficiency.

Fig 5

a) H&E staining of liver sections (X400). b) Representative histograms for the flow cytometric analysis of DNA content in the nuclei of liver cells. c) Quantification of DNA content in the nuclei of liver cells (P: two-tailed Mann-Whitney test for the frequency of 8n nuclei). d) Serum levels of albumin, alanine transaminase (ALT) and alkaline phosphatase. e) Serum levels of creatinine and urea. f) H&E staining of kidney sections (X200). g) Representative flow cytometry profiles of 150.000 lineage- cells for the quantification of stem and progenitor cells (lineage- c-Kit+ Sca-1+, LKS). h) Quantification of LKS and haematopoietic stem cells (LKS CD48-CD150+, HSC) assessed by flow cytometry. i) Quantification of colony forming units–spleen (CFU-S12) by transplantation of test bone marrow into irradiated recipients. In a-i, mice were 8–12 weeks old, C57BL/6 x 129S6/Sv F1 background, error bars represent s.e.m., P: two-tailed Mann-Whitney test. In c, n = 6, 5, 5, 5 and 7. In d, e and h, n = 14, 9, 12, 9 and 4. In i, n = 18, 18, 22 and 22.

Finally, we asked if loss of NER could exacerbate the haematopoietic phenotype of Fanca-/- mice. We used flow cytometry to quantify progenitor cells and HSCs and observed no difference between Xpa-/-Fanca-/- and Fanca-/- controls (Fig 5G and 5h). Next, we performed the spleen colony-forming unit assay, which relies on transplantation and is a functional measure of the frequency of stem and progenitor cells; again, we did not detect any difference between the number of Fanca-/- and Xpa-/-Fanca-/- progenitors (Fig 5I). In all these analyses, Ercc1-/- bone marrow was more compromised compared to Fanca-/-, Xpa-/-Fanca-/- and Csbm/mFanca-/- mice. Although this more severe haematopoietic defect could be confounded by liver and kidney failure, we showed that the HSC compartment is already contracted in utero, prior to severe liver and kidney dysfunction (Fig 1E–1G).

In summary, the phenotype of mice with joint inactivation of NER and FA repair in the C57BL/6 x 129S6/Sv F1 background seems indistinguishable from that of Fanca-/- controls. This is in complete contrast to the severe phenotype of Ercc1-/- mice, which therefore cannot be explained by simultaneous inactivation of NER and ICL repair.

Discussion

Failure to maintain genome integrity leads to cancer, loss of tissue homeostasis and contributes to ageing. The multifunctional nuclease XPF-ERCC1 is a key component of many DNA repair pathways. Here, we interrogate the functions of XPF-ERCC1 genetically yielding insights into which functions are required to protect cells from ICLs and preserve liver, kidney and bone marrow function. The results presented here show that joint inactivation of NER and the FA pathway do not phenocopy XPF-ERCC1 deficiency, both at the cellular level and in adult mice. These findings shed light on the mechanisms of ICL repair and suggest functions of XPF-ERCC1 outside of the canonical excision pathways (S4 Fig).

ICLs are toxic lesions that covalently bind the two strands of DNA together, blocking both transcription and replication. NER removes these adducts in bacteria and yeast. Mammals, however, have evolved the FA pathway, which orchestrates replication-coupled ICL excision. Several cellular and biochemical studies suggest that the NER pathway might also remove ICLs in mammals, outside of replication or during blocked transcription, and that this pathway may act preferentially in certain tissues [29,30]. Here, we first test this hypothesis with an isogenic cellular system, and show that TC-NER provides resistance against classical crosslinking agents (Fig 2), in agreement with previous reports using patient-derived lines [44]. However, the FA ICL repair pathway provides the major route of protection against these agents. Although loss of FANCL completely disables FA repair, we find, surprisingly, that loss of the nuclease XPF-ERCC1 results in much greater hypersensitivity, with XPF-/- cells being far more sensitive to cisplatin and MMC than FANCL-/- cells. Here we show that this increased sensitivity cannot be fully explained by the generation of intrastrand crosslinks or XPF-ERCC1’s function in NER, because XPA-/-FANCL-/- cells that lack NER are still not as sensitive as XPF-/- cells (Fig 3). These data suggest that the XPF-ERCC1 nuclease has an alternative function in ICL repair. One possibility is that XPF-ERCC1 acts at multiple stages of FA-dependant ICL repair, potentially in the resolution of ‘normal’ HR intermediates following unhooking of the crosslink, or dealing with ‘toxic’ DSBs when FA unhooking fails and the replication fork collapses [9,4547] (S4 Fig). The second possibility is that XPF-ERCC1 acts in an entirely separate, FA-independent ICL repair pathway, for example those involving the FAN1 or SNM1A nucleases. In support of this, while SNM1A is non-epistatic with FANCC, SNM1A has an epistatic relationship with XPF-ERCC1, suggesting that these two nucleases function in a common pathway distinct from FA ICL repair [48,49].

We also found that NER and the FA pathway genetically interact to protect cells from formaldehyde, an endogenous source of crosslinks. Interestingly, we did not find a genetic interaction between NER and the FA pathway in response to acetaldehyde, suggesting that these two closely related aldehydes cause a different spectra of DNA lesions. However, this prompted us to investigate if the genetic interaction between NER and the FA pathway extended to mice, to ask if these two pathways cooperate to protect tissues from endogenous DNA damage. Indeed, we find that TC-NER and the FA pathway are jointly required to preserve mouse development in a C57BL/6 isogenic background. It is worth pointing out that Xpa-/- Fanca-/- pups were born at a reduced ratio when compared to Csbm/m Fanca-/-, suggesting that while TC-NER is the major NER pathway protecting mouse development in the absence of the FA pathway, there may be additional redundancy between GG-NER and TC-NER (Fig 4). However, generation of Xpa-/- Fanca-/- and Csbm/m Fanca-/- on a C57BL/6 x 129S6/Sv F1 background rescued the embryonic lethality and revealed phenotypes indistinguishable from single mutant controls (Fig 5). This indicates that NER and FA ICL repair genetically interact, particularly during development, but that this interaction is subtle in adult mice, and heavily affected by genetic background, adding to the list of DNA repair deficient mice whose phenotype is exacerbated in the C57BL/6 background [4143]. The perinatal lethality of FA-deficient mice, as well as Ercc1-/- and Xpg-/- mice, depends strongly on genetic background, being worse in C57BL/6. This suggests that modifier loci in the C57BL/6 background potentiate developmental failure in response to DNA damage. Determining the identity of these modifier loci is an interesting avenue for future research and should shed light on cellular and organismal responses to DNA damage.

Nevertheless, the C57BL/6 x 129S6/Sv F1 background allowed us to compare the phenotype of adult mice lacking the XPF-ERCC1 nuclease and those deficient in NER and/or ICL repair. At the organismal level, HSCs are one of the cell populations which are most affected by loss of the FA ICL repair pathway and this observation is true of FA-deficient mice across all genetic backgrounds. Previous studies have suggested a more severe haematopoietic phenotype in ERCC1 hypomorphic mice compared to the haematopoietic phenotype of FA null mice [20,21,50]. Here, for the first time, we provide a side-by-side comparison of Fanca-/- and Ercc1-/- HSC compartments in embryos and adult mice. Importantly, we show that the more severe HSC defect in Ercc1-/- mice is not solely due to joint inactivation of NER and FA ICL repair, because the haematopoietic defect of Xpa-/-Fanca-/- mice is indistinguishable from Fanca-/- mice. This mirrors the greater sensitivity of XPF-/- HAP1 cells compared to XPA-/-FANCL-/- cells in response to crosslinking agents and points to an additional function of XPF-ERCC1 in the protection of HSCs.

Perhaps the most striking observation from our study is the mild phenotype of Xpa-/-Fanca-/- mice, which phenocopying FANCA deficiency, completely contrasts with the severe, complex and short-lived phenotype of Ercc1-/- animals. This observation challenges the prevailing model that joint inactivation of NER and ICL repair pathways greatly contributes to the severe multi-organ failure of XPF-ERCC1 deficiency and, when put together with previous work, draws our attention to the function of this multifunctional nuclease outside the canonical NER and ICL excision pathways. Multiple NER proteins have been attributed additional roles, both in repair pathways outside NER but also in transcription regulation. XPB and XPD are part of TFIIH, an essential component of the general transcription machinery [51]. CSB and XPG, particularly its C-terminus domain, have also been implicated in the regulation of transcription [5254]. Recent reports have indicated that XPF-ERCC1 also has additional roles in transcription, specifically fine-tuning levels of key target genes through its recruitment of the CCCTC-binding factor (CTCF) chromatin organizer [5558]. Although, the endonuclease activities of both XPF-ERCC1 and XPG are required to recruit CTCF to chromatin in cell lines [58], XPG-catalytic-dead mice (XpgE791A and XpgD811A) develop normally and have normal life-spans [59,60]. Therefore, the physiological relevance of XPF-ERCC1-mediated recruitment of CTCF remains unclear.

On the other hand, XPD, XPB, XPG and CSB are also thought to be involved in transcription-coupled repair (TCR). Mutations in these genes cause CS, characterized by hypersensitivity to sun light, cachexic dwarfism, neurodegeneration and features of premature ageing. This complex phenotype cannot be explained by the sole loss of TC-NER, mostly because patients with mutations in XPA do not develop CS [61]. The term transcription-coupled repair (TCR) encompasses well-documented TC-NER as well as poorly-characterised, non-NER (i.e. XPA-independent) functions of proteins mutated in CS. Importantly, inactivation of TCR dramatically exacerbates the mild phenotype of mice lacking GG-NER [62,63]. Csbm/mXpa-/- and Csbm/mXpc-/- double mutants show short life span, progressive neurodegeneration and cachectic dwarfism. The fact that loss of CSB can potentiate the phenotype of Xpa-/- mice, already deficient for TC-NER, shows that non-NER TCR has redundant functions to NER. It is not known if the nuclease XPF-ERCC1 also operates in non-NER TCR transactions. However, given the phenotypic overlap between Csbm/mXpa-/- and Ercc1-/- mice, and the lack of synergistic phenotype of Xpa-/-Fanca-/- mice shown in this study, we propose that a major component of the phenotype of XPF-ERCC1 deficiency results from joint inactivation of NER and non-NER TCR, rather than NER and ICL repair (S4 Fig). Precisely what these TCR transactions entail, as well as the nature of DNA damage, remain poorly defined and should be the focus of future studies.

The clinical heterogeneity of patients with NER deficiency has challenged the DNA repair field for decades. Only by careful genetic dissection can the contribution of the many factors involved begin to be understood. Here, we used clinically relevant mouse models to dissect two of the most comprehensively studied functions of XPF-ERCC1, its roles in NER and ICL repair, and show that deficiency in both these pathways does not result in liver, kidney and more severe haematopoietic defects. Further genetic dissection of the functions of XPF-ERCC1 will be required to address exactly how this key nuclease protects homeostasis in multiple tissues.

Materials and methods

Ethics statement

All animal experiments undertaken in this study were with approval of the MRC Laboratory of Molecular Biology animal welfare and ethical review body and the UK Home Office under the Animal (Scientific Procedures) Act 1986 license PFC07716E.

Mice

All mice were maintained under specific pathogen-free conditions in individually ventilated cages (Techniplast GM500, Techniplast) on Ligno-cel FS14 spruce bedding (IPS, LTD) with environmental enrichment (fun tunnel, chew stick, and Enviro-Dri nesting material (LBS)) at 19–23 °C with light from 7:00 am to 7:00 pm and fed Dietex CRM pellets (Special Diet Services) ad libitum.

The Fancatm1a(EUCOMM)Wtsi (MGI 4434431, C57BL/6N) and Ercc1tm1a(KOMP)Wtsi (MGI 4362172, C57BL/6) alleles have been described previously [31,33]. Xpatm1Hvs (MGI 1857939, C57BL/6), Ercc6tm1Gvh (Csbm, MGI 1932102, C57BL/6) and Xpctm1Ecf (MGI 1859840, C57BL/6) mice were described previously and a kind gift from G.T. van der Horst, Errol Friedberg and Jan Hoeijmakers [22,39,40]. To generate Xpa-/-Fanca-/-, Xpc-/-Fanca-/- and Csbm/mFanca-/- mice on a pure C57BL/6 background, Fanca+/- mice were crossed with Xpa+/-, Xpc+/- and Csb+/m, respectively. From the resulting progeny we intercrossed NER+/-Fanca+/- to generate all possible genotypes. To further bias the breeding for the generation of double mutants, we intercrossed mice that were both NER-/-Fanca+/-.

To generate mice in a C57BL/6 x 129S6/Sv F1 background, the various C57BL/6 alleles were first backcrossed onto the 129S6/Sv background: Fanca+/- and Csb+/m 10 generations, Xpa+/- 6 generations and Ercc1+/- 7 generations. For Fanca-/- and Ercc1-/- F1 mice, C57BL/6 heterozygous mice were crossed with 129S6/Sv heterozygous mice. For Xpa-/-Fanca-/- and Csbm/mFanca-/- F1 mice, Fanca+/- 129S6/Sv were crossed with Xpa+/- or Csb+/m to generate double heterozygous mice, these mice were then intercrossed to generate Xpa-/-Fanca+/- and Csbm/mFanca+/- 129S6/Sv which were crossed with Xpa-/-Fanca+/- and Csbm/mFanca+/- C57BL/6, respectively. For the phenotyping of C57BL/6 x 129S6/Sv F1 mice, mice were used between 8–12 weeks.

Embryos were generated in a C57BL/6 background and analysed at day E13.5 of development. Females used in timed matings were used between 8 and 18 weeks old.

Cell lines

HAP1 cells (Haplogen) were purchased from Horizon Discovery and cultured in IMDM medium (Gibco) supplemented with 10% dialysed foetal calf serum and penicillin/streptomycin. Cells were grown at 37 °C and 5% CO2. All cell lines used in the study were tested to be mycoplasma-free.

CRISPR/Cas9-mediated gene disruptions in HAP1 cells

Guide sequences for each gene disruption can be found in S1 Table. Plasmids containing each pair of guide sequences were obtained from the Wellcome Trust Sanger Institute. HAP1 cells were transfected with the vector containing guides along with the Cas9 containing PX461 vector using Turbofectin (Origene). Two days post-transfection, GFP+ cells were single-cell sorted into 96-well plates containing medium supplemented with 20% foetal calf serum, using a MoFlo cell sorter (Beckman-Coulter). After 14 days of incubation at 37 °C, individual clones were analysed for expression of the relevant protein by western blotting. Targeted loci were subjected to Sanger sequencing (GATC). S2 Table contains the primers used to amplify the relevant loci by PCR and S3 Table contains the primers used for Sanger Sequencing. For FANCL targeting, LR-PCR was used to screen clones with correct integration of the targeting construct, the primers can be bound in S2 Table.

Western blotting

Cells were lysed for 30 min on ice in RIPA buffer (Thermo Fisher Scientific), including protease inhibitor cocktail (Roche) and phosphatase inhibitor cocktail (Roche). For the detection of FANCD2 in HAP1 cells, cells were treated with MMC 500 ng/ml overnight and protein samples were run on a 3–8% Tris-Acetate gel (Thermo Fisher Scientific). Samples were blotted to a 0.45 μm nitrocellulose membrane. Protein samples were run on a 4–12% Bis-Tris gel (Thermo Fisher Scientific) to detect XPC, XPA, XPF and CSB in HAP1 cells. Antibodies used were anti-XPC (D1M5Y, Cell Signaling, 1:1000), XPF (D3G8C, Cell Signalling, 1:1000), XPA (D9U5U, Cell Signalling, 1:1000), CSB (ab96089, abcam, 1:1000) and FANCD2 polyclonal antisera (1:3000) [64].

Colony survival assay

Haploid HAP1 cells were allowed to diploidise spontaneously and enriched for diploid cells based on DNA content by flow cytometry. All colony survival assays were carried out with diploid HAP1 cells, which were trypsinised and resuspended at a concentration of 2x105 cells/ml. Drugs (mitomycin C, cisplatin, acetaldehyde or formaldehyde) were added at a 2X concentration in a total volume of 2 ml and incubated for 2 hours at 37°C. After 2 hours, two 1/10 serial dilutions were made and 100 μl cells were plated onto a 6 well plate-containing 5 ml IMDM supplemented with 10% dialysed foetal calf serum and penicillin/streptomycin. For UV and X-ray irradiation, cells were diluted to 1x105 cells/ml in 1 ml PBS, irradiated in a 6 well plate, and then immediately after irradiation, cells were spun down and resuspended in 1 ml IMDM and two 1/10 serial dilution were made and 100 μl cells were plated onto 6 well plates. Cells were grown at 37°C for 7 days. For visualization, colonies were washed with PBS and then stained with 6% v/v gluteraldehyde containing 0.5% crystal violet for 1 hour before washing again with PBS.

Histology

Histological analysis was performed on tissues that had been fixed in neutral buffered formalin for 24h. The samples were paraffin embedded and 4 μm sections were cut before staining with haematoxylin and eosin.

Nuclei isolation and DNA content analysis

Liver and kidneys were dissected and passed through a 40-μm filter. Cells were washed twice in LA buffer (250 mM sucrose, 5 mM MgCl2 and 10 mM Tris-HCl, pH 7.4). After washing, the cell pellet was resuspended in 1 ml of buffer LB (2 M sucrose, 1 mM MgCl2 and 10 mM Tris-HCl, pH 7.4) and centrifuged at 16000g for 30 minutes. The white nuclei-containing pellet was resuspended in LA buffer and kept on ice for analysis. For DNA content analysis, nuclei were fixed drop-wise in cold 96% ethanol. Nuclei were pelleted and re-suspended in 400 μl of PBS. Propidium iodide solution (Sigma) was added at a final concentration of 40 μg/ml together with Ribonuclease A (Sigma) at a final concentration of 100 μg/ml. The samples were incubated on ice for one hour and then analysed on LSRII flow cytometer (BD Pharmingen). The data was analysed with FlowJo 10.0.6 (Tree Star).

Serum biochemistry

Serum was collected from 200 μl of whole blood into Microvette 200 conical tubes (MCV200-SER) after centrifugation. Levels of urea, creatinine, aspartate aminotransferase, albumin, and alkaline phosphatase of serum samples were measured using a Siemens Dimension RxL analyser.

HSPC analysis by flow cytometry

Bone marrow cells were isolated from the femora of mutant mice and aged-matched controls by flushing cells and passing them through a 70-μm filter. The following antibodies were used to stain for HSCs: FITC- conjugated lineage cocktail with antibodies anti-CD3e (clone 145-2C11, eBioscience), CD4 (clone H129.19, BD Pharmingen), CD8a (clone 53–6.7, BD Pharmingen), CD11b/Mac-1 (clone M1/70, BD Pharmingen), CD11c (clone N418, eBioscience), Ly-6G/Gr-1 (clone RB6- 8C5, eBioscience), B220 (clone RA3-6B2, BD Pharmingen), FcεR1α (clone MAR-1, eBioscience), TER-119 (clone Ter119, BD Pharmingen), CD41 (clone MWReg30, BD Pharmingen); anti-c-Kit (PerCP-Cy5.5, clone 2B8, eBioscience), anti-Sca-1 (PE-Cy7, clone D7, eBioscience), anti-CD48 (biotin, clone HM48-1, BioLegend) and anti-CD150 (PE, clone TC15- 12F12.2, BioLegend). After staining for 15 minutes in PBS + 2% FCS, the cells were washed and incubated with streptavidin conjugated to Brilliant Violet 421 (BioLegend) for another 15 minutes.

Foetal livers from E13.5 embryos were dissected and placed in 1 ml of PBS + 2% FCS. The foetal livers were triturated gently using a P1000 pipette until a homogenous suspension was formed. The cells were then passed through a 40 μm cell strainer (Falcon) and nucleated cells were counted with 3% acetic acid on a Vi-Cell XR cell viability counter (Beckman Coulter). 10x106 foetal liver cells were spun down for 5 minutes at 1200 rpm and stained as above.

Colony-forming unit spleen (CFU-S12) assay

Mice were sacrificed between 8 and 12 weeks and 1 or 2x105 nucleated bone marrow cells were injected intravenously into recipient mice that had been irradiated with 8 Gy split between two equal 4 Gy doses 4 hours apart. 12 days after transplantation the mice were sacrificed, the spleens were fixed in Bouin’s solution (Sigma) for at least 24 hours and the gross colonies were enumerated and expressed relative to the number of nucleated bone marrow cells injected.

Supporting information

S1 Fig. Generation of Ercc1-/- mice.

a) Ercc1+/- crosses in a C57BL/6 background showing that Ercc1-/- mice are genotyped at sub-Mendelian ratios 2–3 weeks after birth (1.9% instead of the expected 25%, Fisher’s exact test: P < 0.0001). b) Ercc1+/- crosses to generate Ercc1-/- mice in a C57BL/6 x 129S6/Sv F1 background. Although Ercc1-/- mice are genotyped at sub-Mendelian ratios 2–3 weeks after birth (12.5% instead of the expected 25%, Fisher’s exact test: P = 0.0002), the mixed genetic background rescues the lethality observed in the C57BL/6 background. c) Survival of Ercc1-/- and control mice in C57BL/6 and C57BL/6 x 129S6/Sv F1 genetic backgrounds.

(TIF)

S2 Fig. Generation of HAP1 knock out lines.

a) Maps of human NER genes. The inset shows the nucleotide and predicted amino acid sequence of wild type and knock out HAP1 lines, generated by introducing deletions with CRISPR/Cas9, see Methods for details. b) Map of the human FANCL gene and targeting of exon 8 to generate isogenic disruptions in FANCL. c) Agarose gel showing disruption of the FANCL locus by long-range PCR. Primers hybridise outside the homology arms and within the targeting construct.

(TIF)

S3 Fig. Joint inactivation of TCR and FA crosslink repair does not phenocopy XPF-ERCC1 deficiency.

a) Crosses for the generation of double mutant mice in a C57BL/6 x 129S6/Sv F1 background, pups were genotyped 2–3 weeks after birth (P: Fisher’s exact test, compared to expected numbers). b) Weights of 8-week-old females in a C57BL/6 x 129S6/Sv F1 background (P: two-tailed Mann-Whitney test, n = 9, 3, 5, 3, 4, 5 and 7). c) Quantification of DNA content in the nuclei of liver cells (P: two-tailed Mann-Whitney test for the frequency of 8n nuclei, n = 6, 5, 5, 5 and 7). d) Serum levels of albumin, alanine transaminase (ALT) and alkaline phosphatase. e) Serum levels of creatinine and urea. f) Quantification of stem and progenitor cells (lineage- c-Kit+ Sca-1+, LKS) and haematopoietic stem cells (LKS CD48- CD150+, HSC) assessed by flow cytometry. In d-f, mice were 8–12 weeks old, C57BL/6 x 129S6/Sv F1 background, error bars represent s.e.m., P: two-tailed Mann-Whitney test. n = 14, 6, 12, 6 and 4.

(TIF)

S4 Fig. Model of the interactions between DNA repair pathways that converge on the nuclease XPF-ERCC1.

a) NER and FA ICL repair interact to protect against certain crosslinkers in vitro and to ensure normal development in a C57BL/6 background. b) XPF-ERCC1 has a role in ICL repair outside NER and ICL unhooking, potentially the repair of DNA double strand breaks (DSBs). c) The XPF-ERCC1 phenotype is likely due to deficiency in NER and non-NER TCR rather than NER and FA ICL repair. How exactly XPF-ERCC1 operates in TCR, and the nature of this damage, remains to be established.

(TIF)

S1 Table. gRNAs for the generation of CRISPR knock outs.

(DOCX)

S2 Table. Oligos for the screening of CRISPR knock outs by PCR.

(DOCX)

S3 Table. Oligos for Sanger sequencing of PCR products.

(DOCX)

Acknowledgments

We are grateful to Ketan J. Patel for creating a stimulating research environment, and giving us the freedom, support and resources to pursue our own ideas. We thank Errol Friedberg, G.T. van der Horst and Jan Hoeijmakers for sharing the Xpc-/-, Xpa-/- and Csbm/m mice. We thank the ARES staff, Biomed and the LMB Genotyping service for their help with mouse work; and members of the Patel and Crossan laboratories for critical reading of the manuscript. The Human Research Tissue Bank (supported by the NIHR Cambridge Biomedical Research Centre) processed histology.

Data Availability

All relevant data are within the manuscript and its Supporting Information files

Funding Statement

This work was supported by the MRC Laboratory of Molecular Biology. L.M. is supported by a CRUK Program grant awarded to Ketan J. Patel. J.I.G. was supported by the Wellcome Trust Investigator Grant awarded to Ketan J. Patel, King’s College, Cambridge and the Hubrecht Institute. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript

References

  • 1.Lindahl T. Instability and decay of the primary structure of DNA. Nature. 1993;362: 709–15. 10.1038/362709a0 [DOI] [PubMed] [Google Scholar]
  • 2.Marteijn JA, Lans H, Vermeulen W, Hoeijmakers JHJ. Understanding nucleotide excision repair and its roles in cancer and ageing. Nat Rev Mol Cell Biol. 2014;15: 465–81. 10.1038/nrm3822 [DOI] [PubMed] [Google Scholar]
  • 3.Klein Douwel D, Boonen RACM, Long DT, Szypowska AA, Räschle M, Walter JC, et al. XPF-ERCC1 acts in Unhooking DNA interstrand crosslinks in cooperation with FANCD2 and FANCP/SLX4. Mol Cell. 2014;54: 460–71. 10.1016/j.molcel.2014.03.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Hodskinson MRG, Silhan J, Crossan GP, Garaycoechea JI, Mukherjee S, Johnson CM, et al. Mouse SLX4 is a tumor suppressor that stimulates the activity of the nuclease XPF-ERCC1 in DNA crosslink repair. Mol Cell. 2014;54: 472–84. 10.1016/j.molcel.2014.03.014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Langevin F, Crossan GP, Rosado I V., Arends MJ, Patel KJ. Fancd2 counteracts the toxic effects of naturally produced aldehydes in mice. Nature. 2011;475: 53–59. 10.1038/nature10192 [DOI] [PubMed] [Google Scholar]
  • 6.Garaycoechea JI, Crossan GP, Langevin F, Mulderrig L, Louzada S, Yang F, et al. Alcohol and endogenous aldehydes damage chromosomes and mutate stem cells. Nature. 2018;553: 171–177. 10.1038/nature25154 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Pontel LB, Rosado I V., Burgos-Barragan G, Garaycoechea JI, Yu R, Arends MJ, et al. Endogenous formaldehyde is a hematopoietic stem cell genotoxin and metabolic carcinogen. Mol Cell. 2015;60: 177–188. 10.1016/j.molcel.2015.08.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Knipscheer P, Räschle M, Smogorzewska A, Enoiu M, Ho TV, Schärer OD, et al. The Fanconi anemia pathway promotes replication-dependent DNA interstrand cross-link repair. Science. 2009;326: 1698–701. 10.1126/science.1182372 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Ahmad A, Robinson AR, Duensing A, van Drunen E, Beverloo HB, Weisberg DB, et al. ERCC1-XPF Endonuclease Facilitates DNA Double-Strand Break Repair. Mol Cell Biol. 2008;28: 5082–5092. 10.1128/MCB.00293-08 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bradford PT, Goldstein AM, Tamura D, Khan SG, Ueda T, Boyle J, et al. Cancer and neurologic degeneration in xeroderma pigmentosum: long term follow-up characterises the role of DNA repair. J Med Genet. 2011;48: 168–76. 10.1136/jmg.2010.083022 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Laugel V. Cockayne syndrome: the expanding clinical and mutational spectrum. Mech Ageing Dev. 2013;134: 161–70. 10.1016/j.mad.2013.02.006 [DOI] [PubMed] [Google Scholar]
  • 12.Kutler DI, Singh B, Satagopan J, Batish SD, Berwick M, Giampietro PF, et al. A 20-year perspective on the International Fanconi Anemia Registry (IFAR). Blood. 2003;101: 1249–56. 10.1182/blood-2002-07-2170 [DOI] [PubMed] [Google Scholar]
  • 13.Niedernhofer LJ, Garinis GA, Raams A, Lalai AS, Robinson AR, Appeldoorn E, et al. A new progeroid syndrome reveals that genotoxic stress suppresses the somatotroph axis. Nature. 2006;444: 1038–43. 10.1038/nature05456 [DOI] [PubMed] [Google Scholar]
  • 14.Jaspers NGJ, Raams A, Silengo MC, Wijgers N, Niedernhofer LJ, Robinson AR, et al. First reported patient with human ERCC1 deficiency has cerebro-oculo-facio-skeletal syndrome with a mild defect in nucleotide excision repair and severe developmental failure. Am J Hum Genet. 2007;80: 457–66. 10.1086/512486 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Kashiyama K, Nakazawa Y, Pilz DT, Guo C, Shimada M, Sasaki K, et al. Malfunction of nuclease ERCC1-XPF results in diverse clinical manifestations and causes Cockayne syndrome, xeroderma pigmentosum, and Fanconi anemia. Am J Hum Genet. 2013;92: 807–19. 10.1016/j.ajhg.2013.04.007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.McWhir J, Selfridge J, Harrison DJ, Squires S, Melton DW. Mice with DNA repair gene (ERCC-1) deficiency have elevated levels of p53, liver nuclear abnormalities and die before weaning. Nat Genet. 1993;5: 217–24. 10.1038/ng1193-217 [DOI] [PubMed] [Google Scholar]
  • 17.Weeda G, Donker I, de Wit J, Morreau H, Janssens R, Vissers CJ, et al. Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. Curr Biol. 1997;7: 427–39. Available: http://www.ncbi.nlm.nih.gov/pubmed/9197240 10.1016/s0960-9822(06)00190-4 [DOI] [PubMed] [Google Scholar]
  • 18.Tian M, Shinkura R, Shinkura N, Alt FW. Growth retardation, early death, and DNA repair defects in mice deficient for the nucleotide excision repair enzyme XPF. Mol Cell Biol. 2004;24: 1200–5. 10.1128/MCB.24.3.1200-1205.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Selfridge J, Hsia KT, Redhead NJ, Melton DW. Correction of liver dysfunction in DNA repair-deficient mice with an ERCC1 transgene. Nucleic Acids Res. 2001;29: 4541–50. 10.1093/nar/29.22.4541 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Prasher JM, Lalai AS, Heijmans-Antonissen C, Ploemacher RE, Hoeijmakers JHJ, Touw IP, et al. Reduced hematopoietic reserves in DNA interstrand crosslink repair-deficient Ercc1-/- mice. EMBO J. 2005;24: 861–871. 10.1038/sj.emboj.7600542 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Cho JS, Kook SH, Robinson AR, Niedernhofer LJ, Lee BC. Cell autonomous and nonautonomous mechanisms drive hematopoietic stem/progenitor cell loss in the absence of DNA repair. Stem Cells. 2013;31: 511–525. 10.1002/stem.1261 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.de Vries A, van Oostrom CT, Hofhuis FM, Dortant PM, Berg RJ, de Gruijl FR, et al. Increased susceptibility to ultraviolet-B and carcinogens of mice lacking the DNA excision repair gene XPA. Nature. 1995;377: 169–73. 10.1038/377169a0 [DOI] [PubMed] [Google Scholar]
  • 23.Cheng NC, van de Vrugt HJ, van der Valk MA, Oostra AB, Krimpenfort P, de Vries Y, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet. 2000;9: 1805–11. 10.1093/hmg/9.12.1805 [DOI] [PubMed] [Google Scholar]
  • 24.Río P, Segovia JC, Hanenberg H, Casado JA, Martínez J, Göttsche K, et al. In vitro phenotypic correction of hematopoietic progenitors from Fanconi anemia group A knockout mice. Blood. 2002;100: 2032–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/12200363 [PubMed] [Google Scholar]
  • 25.Sladek FM, Munn MM, Rupp WD, Howard-Flanders P. In vitro repair of psoralen-DNA cross-links by RecA, UvrABC, and the 5’-exonuclease of DNA polymerase I. J Biol Chem. 1989;264: 6755–65. Available: http://www.ncbi.nlm.nih.gov/pubmed/2708342 [PubMed] [Google Scholar]
  • 26.Van Houten B, Gamper H, Holbrook SR, Hearst JE, Sancar A. Action mechanism of ABC excision nuclease on a DNA substrate containing a psoralen crosslink at a defined position. Proc Natl Acad Sci U S A. 1986;83: 8077–81. 10.1073/pnas.83.21.8077 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.McHugh PJ, Sones WR, Hartley JA. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol. 2000;20: 3425–33. 10.1128/mcb.20.10.3425-3433.2000 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Sarkar S, Davies AA, Ulrich HD, McHugh PJ. DNA interstrand crosslink repair during G1 involves nucleotide excision repair and DNA polymerase ζ. EMBO J. 2006;25: 1285–1294. 10.1038/sj.emboj.7600993 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Muniandy PA, Thapa D, Thazhathveetil AK, Liu S, Seidman MM. Repair of laser-localized DNA interstrand cross-links in G1 phase mammalian cells. J Biol Chem. 2009;284: 27908–17. 10.1074/jbc.M109.029025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Enoiu M, Jiricny J, Schärer OD. Repair of cisplatin-induced DNA interstrand crosslinks by a replication-independent pathway involving transcription-coupled repair and translesion synthesis. Nucleic Acids Res. 2012;40: 8953–8964. 10.1093/nar/gks670 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Hill R, Crossan GP. DNA crosslink repair safeguards genomic stability during pre-meiotic germ cell development. Nat Genet. 2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Parmar K, Kim J, Sykes SM, Shimamura A, Stuckert P, Zhu K, et al. Hematopoietic stem cell defects in mice with deficiency of Fancd2 or Usp1. Stem Cells. 2010;28: 1186–95. 10.1002/stem.437 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Garaycoechea JI, Crossan GP, Langevin F, Daly M, Arends MJ, Patel KJ. Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function. Nature. 2012;489: 571–575. 10.1038/nature11368 [DOI] [PubMed] [Google Scholar]
  • 34.Kamimae-Lanning AN, Goloviznina NA, Kurre P. Fetal origins of hematopoietic failure in a murine model of Fanconi anemia. Blood. 2013;121: 2008–2012. 10.1182/blood-2012-06-439679 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Domenech C, Maillard L, Rousseau A, Guidez F, Petit L, Pla M, et al. Studies in an early development window unveils a severe HSC defect in both murine and human Fanconi Anemia. Stem cell reports. 2018;11: 1075–1091. 10.1016/j.stemcr.2018.10.001 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Huang JC, Zamble DB, Reardon JT, Lippard SJ, Sancar A. HMG-domain proteins specifically inhibit the repair of the major DNA adduct of the anticancer drug cisplatin by human excision nuclease. Proc Natl Acad Sci U S A. 1994;91: 10394–8. 10.1073/pnas.91.22.10394 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Cheng G, Shi Y, Sturla SJ, Jalas JR, McIntee EJ, Villalta PW, et al. Reactions of formaldehyde plus acetaldehyde with deoxyguanosine and DNA: formation of cyclic deoxyguanosine adducts and formaldehyde cross-links. Chem Res Toxicol. 2003;16: 145–52. 10.1021/tx025614r [DOI] [PubMed] [Google Scholar]
  • 38.Kuykendall JR, Bogdanffy MS. Efficiency of DNA-histone crosslinking induced by saturated and unsaturated aldehydes in vitro. Mutat Res. 1992;283: 131–6. 10.1016/0165-7992(92)90145-8 [DOI] [PubMed] [Google Scholar]
  • 39.Cheo DL, Ruven HJT, Meira LB, Hammer RE, Burns DK, Tappe NJ, et al. Characterization of defective nucleotide excision repair in XPC mutant mice. Mutat Res. 1997;374: 1–9. 10.1016/s0027-5107(97)00046-8 [DOI] [PubMed] [Google Scholar]
  • 40.van der Horst GT, van Steeg H, Berg RJ, van Gool AJ, de Wit J, Weeda G, et al. Defective transcription-coupled repair in Cockayne syndrome B mice is associated with skin cancer predisposition. Cell. 1997;89: 425–35. 10.1016/s0092-8674(00)80223-8 [DOI] [PubMed] [Google Scholar]
  • 41.Barnhoorn S, Uittenboogaard LM, Jaarsma D, Vermeij WP, Tresini M, Weymaere M, et al. Cell-autonomous progeroid changes in conditional mouse models for repair endonuclease XPG deficiency. PLoS Genet. 2014;10: e1004686 10.1371/journal.pgen.1004686 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Ghezraoui H, Oliveira C, Becker JR, Bilham K, Moralli D, Anzilotti C, et al. 53BP1 cooperation with the REV7-shieldin complex underpins DNA structure-specific NHEJ. Nature. 2018;560: 122–127. 10.1038/s41586-018-0362-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Bellelli R, Borel V, Logan C, Svendsen J, Cox DE, Nye E, et al. Polε Instability Drives Replication Stress, Abnormal Development, and Tumorigenesis. Mol Cell. 2018;70: 707–721.e7. 10.1016/j.molcel.2018.04.008 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Furuta T, Ueda T, Aune G, Sarasin A, Kraemer KH, Pommier Y. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res. 2002;62: 4899–4902. [PubMed] [Google Scholar]
  • 45.Bennardo N, Cheng A, Huang N, Stark JM. Alternative-NHEJ is a mechanistically distinct pathway of mammalian chromosome break repair. PLoS Genet. 2008;4: e1000110 10.1371/journal.pgen.1000110 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Al-Minawi AZ, Saleh-Gohari N, Helleday T. The ERCC1/XPF endonuclease is required for efficient single-strand annealing and gene conversion in mammalian cells. Nucleic Acids Res. 2008;36: 1–9. 10.1093/nar/gkm888 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Motycka TA, Bessho T, Post SM, Sung P, Tomkinson AE. Physical and functional interaction between the XPF/ERCC1 endonuclease and hRad52. J Biol Chem. 2004;279: 13634–9. 10.1074/jbc.M313779200 [DOI] [PubMed] [Google Scholar]
  • 48.Ishiai M, Kimura M, Namikoshi K, Yamazoe M, Yamamoto K, Arakawa H, et al. DNA cross-link repair protein SNM1A interacts with PIAS1 in nuclear focus formation. Mol Cell Biol. 2004;24: 10733–41. 10.1128/MCB.24.24.10733-10741.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Wang AT, Sengerová B, Cattell E, Inagawa T, Hartley JM, Kiakos K, et al. Human SNM1A and XPF-ERCC1 collaborate to initiate DNA interstrand cross-link repair. Genes Dev. 2011;25: 1859–70. 10.1101/gad.15699211 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Verhagen-Oldenampsen JHE, Haanstra JR, van Strien PMH, Valkhof M, Touw IP, von Lindern M. Loss of Ercc1 Results in a Time- and Dose-Dependent Reduction of Proliferating Early Hematopoietic Progenitors. Anemia. 2012;2012: 1–9. 10.1155/2012/783068 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Compe E, Egly J-M. TFIIH: when transcription met DNA repair. Nat Rev Mol Cell Biol. 2012;13: 343–54. 10.1038/nrm3350 [DOI] [PubMed] [Google Scholar]
  • 52.Fousteri M, Vermeulen W, van Zeeland AA, Mullenders LHF. Cockayne syndrome A and B proteins differentially regulate recruitment of chromatin remodeling and repair factors to stalled RNA polymerase II in vivo. Mol Cell. 2006;23: 471–82. 10.1016/j.molcel.2006.06.029 [DOI] [PubMed] [Google Scholar]
  • 53.Sarker AH, Tsutakawa SE, Kostek S, Ng C, Shin DS, Peris M, et al. Recognition of RNA polymerase II and transcription bubbles by XPG, CSB, and TFIIH: insights for transcription-coupled repair and Cockayne Syndrome. Mol Cell. 2005;20: 187–98. 10.1016/j.molcel.2005.09.022 [DOI] [PubMed] [Google Scholar]
  • 54.Ito S, Kuraoka I, Chymkowitch P, Compe E, Takedachi A, Ishigami C, et al. XPG stabilizes TFIIH, allowing transactivation of nuclear receptors: implications for Cockayne syndrome in XP-G/CS patients. Mol Cell. 2007;26: 231–43. 10.1016/j.molcel.2007.03.013 [DOI] [PubMed] [Google Scholar]
  • 55.Kamileri I, Karakasilioti I, Sideri A, Kosteas T, Tatarakis A, Talianidis I, et al. Defective transcription initiation causes postnatal growth failure in a mouse model of nucleotide excision repair (NER) progeria. Proc Natl Acad Sci U S A. 2012;109: 2995–3000. 10.1073/pnas.1114941109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 56.Le May N, Mota-Fernandes D, Vélez-Cruz R, Iltis I, Biard D, Egly JM. NER Factors Are Recruited to Active Promoters and Facilitate Chromatin Modification for Transcription in the Absence of Exogenous Genotoxic Attack. Mol Cell. 2010;38: 54–66. 10.1016/j.molcel.2010.03.004 [DOI] [PubMed] [Google Scholar]
  • 57.Chatzinikolaou G, Apostolou Z, Aid-Pavlidis T, Ioannidou A, Karakasilioti I, Papadopoulos GL, et al. ERCC1-XPF cooperates with CTCF and cohesin to facilitate the developmental silencing of imprinted genes. Nat Cell Biol. 2017;19: 421–432. 10.1038/ncb3499 [DOI] [PubMed] [Google Scholar]
  • 58.Le May N, Fradin D, Iltis I, Bougnères P, Egly JM. XPG and XPF Endonucleases Trigger Chromatin Looping and DNA Demethylation for Accurate Expression of Activated Genes. Mol Cell. 2012;47: 622–632. 10.1016/j.molcel.2012.05.050 [DOI] [PubMed] [Google Scholar]
  • 59.Shiomi N, Kito S, Oyama M, Matsunaga T, Harada Y-N, Ikawa M, et al. Identification of the XPG Region That Causes the Onset of Cockayne Syndrome by Using Xpg Mutant Mice Generated by the cDNA-Mediated Knock-In Method. Mol Cell Biol. 2004;24: 3712–3719. 10.1128/MCB.24.9.3712-3719.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Tian M, Jones DA, Smith M, Shinkura R, Alt FW. Deficiency in the Nuclease Activity of Xeroderma Pigmentosum G in Mice Leads to Hypersensitivity to UV Irradiation. Mol Cell Biol. 2004;24: 2237–2242. 10.1128/MCB.24.6.2237-2242.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.DiGiovanna JJ, Kraemer KH. Shining a light on xeroderma pigmentosum. J Invest Dermatol. 2012;132: 785–96. 10.1038/jid.2011.426 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.van der Pluijm I, Garinis GA, Brandt RMC, Gorgels TGMF, Wijnhoven SW, Diderich KEM, et al. Impaired genome maintenance suppresses the growth hormone—insulin-like growth factor 1 axis in mice with Cockayne syndrome. PLoS Biol. 2007;5: e2 10.1371/journal.pbio.0050002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Jaarsma D, van der Pluijm I, de Waard MC, Haasdijk ED, Brandt R, Vermeij M, et al. Age-related neuronal degeneration: Complementary roles of nucleotide excision repair and transcription-coupled repair in preventing neuropathology. PLoS Genet. 2011;7: 6–8. 10.1371/journal.pgen.1002405 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64.Pace P, Johnson M, Tan WM, Mosedale G, Sng C, Hoatlin M, et al. FANCE: the link between Fanconi anaemia complex assembly and activity. EMBO J. 2002;21: 3414–23. 10.1093/emboj/cdf355 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

Gregory S Barsh, Nancy Maizels

3 Nov 2019

* Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out. *

Dear Dr Garaycoechea,

Thank you very much for submitting your Research Article entitled 'XPF-ERCC1 protects liver, kidney and blood homeostasis outside the canonical excision repair pathways' to PLOS Genetics. Your manuscript was fully evaluated at the editorial level and by independent peer reviewers. The reviewers appreciated the attention to an important topic but identified some aspects of the manuscript that should be improved.  Revision will require a more thorough discussion that addresses some very thoughtful questions raised by the reviewers, but you need not include new experimental results unless you opt to do so.

We therefore ask you to modify the manuscript according to the review recommendations before we can consider your manuscript for acceptance. Your revisions should address the specific points made by each reviewer.

In addition we ask that you:

1) Provide a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript.

2) Upload a Striking Image with a corresponding caption to accompany your manuscript if one is available (either a new image or an existing one from within your manuscript). If this image is judged to be suitable, it may be featured on our website. Images should ideally be high resolution, eye-catching, single panel square images. For examples, please browse our archive. If your image is from someone other than yourself, please ensure that the artist has read and agreed to the terms and conditions of the Creative Commons Attribution License. Note: we cannot publish copyrighted images.

We hope to receive your revised manuscript within the next 30 days. If you anticipate any delay in its return, we would ask you to let us know the expected resubmission date by email to plosgenetics@plos.org.

If present, accompanying reviewer attachments should be included with this email; please notify the journal office if any appear to be missing. They will also be available for download from the link below. You can use this link to log into the system when you are ready to submit a revised version, having first consulted our Submission Checklist.

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Please be aware that our data availability policy requires that all numerical data underlying graphs or summary statistics are included with the submission, and you will need to provide this upon resubmission if not already present. In addition, we do not permit the inclusion of phrases such as "data not shown" or "unpublished results" in manuscripts. All points should be backed up by data provided with the submission.

PLOS has incorporated Similarity Check, powered by iThenticate, into its journal-wide submission system in order to screen submitted content for originality before publication. Each PLOS journal undertakes screening on a proportion of submitted articles. You will be contacted if needed following the screening process.

To resubmit, you will need to go to the link below and 'Revise Submission' in the 'Submissions Needing Revision' folder.

[LINK]

Please let us know if you have any questions while making these revisions.

Yours sincerely,

Nancy Maizels, Ph.D.

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: Mulderrig and colleagues present a descriptive genetic study of the interaction between two key pathways thought to defend against DNA interstrand crosslinks (ICLs) in mammals, namely nucleotide excision repair (NER) and factors deficient in Fanconi anemia (FA). While little in the way of novel mechanism is revealed, much can be surmised from the detailed phenotypic analysis, and it is my view that this is an important and timely contribution. The reliance on the transcription-coupled aspects of NER (TC-NER) have not been previously addressed or demonstrated in a systematic fashion. The MS is well-written, the data support the conclusions, the experiments are relatively thorough and the work is generally of good quality.

My only comments are as follows:

1. It has been suggested on a number of occasions that some rodent cell types are deficient, or at least show reduced, GG-NER, possibly due to low DDB2 levels, originally referred to as the 'rodent repairadox'. It remains unclear for many cell types whether this is really the case in vivo, but the possibility that certain rodent cells types could be less efficient in performing GG-NER than perhaps human cells are should be acknowledged and its ramifications briefly discussed.

2. In the Discussion section, few alternative suggestions are proposed for the identity of the XPF-ERCC1 dependent ICL repair pathway(s) that act in addition to TC-NER and the FA pathways. It would be nice to see the authors 'stick their necks out' and speculate a little on this point: could it/they be FAN1, SNM1A or mismatch repair-related?

Reviewer #2: Loss of the XPF/ERCC1 nuclease complex results in a more profound phenotype than absence of other nucleotide excision repair (NER) genes. Ercc1-/- mice are born at substantially less than expected frequencies and die shortly after birth. In humans, complete inactivation of either XPF or ERCC1 is incompatible with viability. Although the basis of the apparently absolute requirement for XPF/ERCC1 remains uncertain, it is known that the complex is important for multiple DNA transactions: NER (both global and transcription coupled), but also interstrand crosslink (ICL) repair via the Fanconi Anemia (FA) pathway. Additionally, ERCC1/XPF has a function in telomere maintenance, contributes to repair of double strand breaks in both homology directed and end joining pathways, and is involved in the repair of abasic lesions. Presumably the profound phenotype of XPF/ERCC1 deficiency reflects diminished efficacy of the collective of these, or as yet unidentified, pathways.

In an effort to clarify the basis for the extreme phenotype the authors of this submission have examined the response to various DNA damaging agents, including acetaldehyde, formaldehyde, cisplatin and MMC in cells either lacking ERCC1, or XPA (representing loss of both GG and TC-NER), or FANCL (a key FA gene), or both XPA and FANCL. XPA and the FANCL double knockout cells were not as sensitive to cisplatin, MMC, or acetaldehyde as ERCC1-/- cells. These results emphasized the greater pathology of Ercc1-/- as compared to loss of both NER pathways, or the FA pathway, or the combined pathways. They argued that Ercc1 performed repair functions additional to those of NER and FA. These results and conclusion contrasted with the results with formaldehyde treated cells in which the FANCL-/-XPA-/- cells were just as sensitive as the ERCC1-/- cells.

The authors also studied the effect of combined NER and FA deficiency on mouse development. Xpa-/- Fanca-/- C57BL/6 pups were born as infrequently as Ercc1-/- animals. This observation was further dissected by examining pup frequencies in Fanca-/- Xpc-/- or Fanca-/- Csb-/- C57BL/6. Csb (mutant in Cockayne Syndrome and required for TCR) was chosen because it restricted the deficiency to TCR. The absence of Xpc in the Fanca-/- background did not affect birth frequencies, while Csb deficiency reduced them by half, significant, but not as profound as the Ercc1-/- or Xpa-/- Fanca-/- reduction. This result focused attention on the requirement for TC-NER and FA in normal development, but implied that additional ERCC1 pathways were also important.

The analyses of Ercc1 knockout was also performed in F1 hybrids of C57BL/6 crossed with 129S6/Sv, a strain that suppresses the developmental severity of Ercc1 loss. The role of the NER and FA pathways in postnatal life was examined in the F1 hybrids. Xpa-/- Fanca-/- pups were born at normal frequencies and examination of liver, kidney, and hematopoietic tissues indicated that the Ercc1-/- animals were more severely compromised than either the Xpa-/-Fanca-/- or Csb-/-Fanca-/- animals.

In their Discussion the authors cite work from van der Pluijm et al, who studied Csb and Csb/Xpa deficient C57BL/6 mice, whose birth frequencies were reduced but not as severely as Ercc1-/- mice.

Critique:

This paper presents a series of thoughtfully designed and detailed analyses to address the question: do the NER and FA pathways account for the activities of XPF/ERCC1? The answer seems to be: it depends on the specifics of the assay. This rather mixed conclusion, in a narrative that twists and turns, should be clarified with some additional data and discussion. Otherwise it seems to be two parallel reports-one describing results with one damaging agent and mouse strain that conclude the affirmative, while the other presents the contrary view based on assays with different damaging agents and mouse background.

1. In the experiments with HAP1 knockout cells the authors found that the XPA/ FANCL double KO cells were as sensitive to formaldehyde as the XPF KO. Consequently, the elements of the XPF pathway that conferred protection to formaldehyde were duplicated by NER and FA. In contrast, the sensitivity of XPF KO cells to MMC, cisplatin, and acetaldehyde was not completely captured by XPA/FANCL KO. This implied that while these compounds generated adducts repaired by NER and FA, they also produce toxic structure (s), not formed by formaldehyde, that is/are resistant to NER and FA, but resolved by XPF. XPF/ERCC1 contributes to various forms of double strand break (DSB) repair. Recent work in yeast (Cell Cycle 16, 45, 2017) suggest an involvement in homologous recombination pathways in the repair of acetaldehyde damage. Sensitivity to crosslinking agents is a mark of many HR deficiencies. The authors raise the possibility of ERCC1 participation in the repair of DSBs in the context of the compound sensitivity experiments. Do cells treated with these compounds show evidence for DSBs, perhaps replication related, that formaldehyde treated cells do not? Some simple immunofluorescence analyses or comet assays would address this.

2. The adverse effects of FA deficiencies are interpreted as reflecting the activity of the pathway in ICL repair. Although this is reasonable, there is a school of thought that adds sensitivity to inflammatory mediators as an important aspect of FA. This is a feature that might have profound consequences during development and should be mentioned.

3. In C57BL/6 mice Xpa/Fanca KO recapitulates the low birth yields seen with Ercc1 KO mice. Consequently, it appears that the NER and (at least some aspect of) the FA pathways substitute for Xpf/Ercc1 during early mouse development. The authors discuss this and conclude that the combination of the TCR and FA pathways “preserve development”. However, the decline in live births in the Csb/Fanca pups is not as great as in the Xpa/Fanca background. Is there another, non NER, role for XPA?

4. The results of with C57BL/6 were confounded by the suppression of effect of the Xpa/Fanca knock out in the C57BL/6 x 129S6/Sv cross. The experiments with the crossed animals are more difficult to interpret, given the amelioration of phenotypes by unknown modifiers supplied by 129S6/Sv. The operating assumption with the F1 hybrid is that the “modifying” component does not affect the deficiency under study. For example, the results indicate that Ercc1 loss is more consequential than Xpa/Fanca for various tissue markers, in the F1. Is it possible that the 129S6/Sv strain supplies a suppressor of FA deficiency, making the Xpa/Fanca KO F1 strain still functionally Xpa-/- but with diminished influence of FA inactivity? Are the cells from the F1 “FA-/-“ as defective in Fanconi pathway functions (like ICL repair) as C57BL/6 “FA-/- “? Pace et al demonstrated in a well known study (Science 2010) that Ku70 ”corrupts DNA repair in the absence of the FA pathway”. Loss of Ku reduced sensitivity to ICLs and chromosome instability. Does the 129S6/Sv strain contribute something like this to the F1?

5. In the end the authors reach the conclusion that the lack of TCR, of both NER and non NER lesions, accounts for much of the phenotype of XPF-ERCC1 deficiency. While that may make a central contribution, the results across the study are so influenced by experimental design so as to restrict conclusions to the specific conditions of the analysis.

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Genetics data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Reviewer #2: Yes

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Decision Letter 1

Gregory S Barsh, Nancy Maizels

5 Dec 2019

Dear Juan,

We are pleased to inform you that your manuscript entitled "XPF-ERCC1 protects liver, kidney and blood homeostasis outside the canonical excision repair pathways" has been editorially accepted for publication in PLOS Genetics. Congratulations!

Before your submission can be formally accepted and sent to production you will need to complete our formatting changes, which you will receive in a follow up email. Please be aware that it may take several days for you to receive this email; during this time no action is required by you. Please note: the accept date on your published article will reflect the date of this provisional accept, but your manuscript will not be scheduled for publication until the required changes have been made.

Once your paper is formally accepted, an uncorrected proof of your manuscript will be published online ahead of the final version, unless you’ve already opted out via the online submission form. If, for any reason, you do not want an earlier version of your manuscript published online or are unsure if you have already indicated as such, please let the journal staff know immediately at plosgenetics@plos.org.

In the meantime, please log into Editorial Manager at https://www.editorialmanager.com/pgenetics/, click the "Update My Information" link at the top of the page, and update your user information to ensure an efficient production and billing process. Note that PLOS requires an ORCID iD for all corresponding authors. Therefore, please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field.  This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager.

If you have a press-related query, or would like to know about one way to make your underlying data available (as you will be aware, this is required for publication), please see the end of this email. If your institution or institutions have a press office, please notify them about your upcoming article at this point, to enable them to help maximise its impact. Inform journal staff as soon as possible if you are preparing a press release for your article and need a publication date.

Thank you again for supporting open-access publishing; we are looking forward to publishing your work in PLOS Genetics!

Yours sincerely,

Nancy Maizels, Ph.D.

Associate Editor

PLOS Genetics

Gregory Barsh

Editor-in-Chief

PLOS Genetics

www.plosgenetics.org

Twitter: @PLOSGenetics

----------------------------------------------------

Comments from the reviewers (if applicable):

----------------------------------------------------

Data Deposition

If you have submitted a Research Article or Front Matter that has associated data that are not suitable for deposition in a subject-specific public repository (such as GenBank or ArrayExpress), one way to make that data available is to deposit it in the Dryad Digital Repository. As you may recall, we ask all authors to agree to make data available; this is one way to achieve that. A full list of recommended repositories can be found on our website.

The following link will take you to the Dryad record for your article, so you won't have to re‐enter its bibliographic information, and can upload your files directly: 

http://datadryad.org/submit?journalID=pgenetics&manu=PGENETICS-D-19-01655R1

More information about depositing data in Dryad is available at http://www.datadryad.org/depositing. If you experience any difficulties in submitting your data, please contact help@datadryad.org for support.

Additionally, please be aware that our data availability policy requires that all numerical data underlying display items are included with the submission, and you will need to provide this before we can formally accept your manuscript, if not already present.

----------------------------------------------------

Press Queries

If you or your institution will be preparing press materials for this manuscript, or if you need to know your paper's publication date for media purposes, please inform the journal staff as soon as possible so that your submission can be scheduled accordingly. Your manuscript will remain under a strict press embargo until the publication date and time. This means an early version of your manuscript will not be published ahead of your final version. PLOS Genetics may also choose to issue a press release for your article. If there's anything the journal should know or you'd like more information, please get in touch via plosgenetics@plos.org.

Acceptance letter

Gregory S Barsh, Nancy Maizels

17 Dec 2019

PGENETICS-D-19-01655R1

XPF-ERCC1 protects liver, kidney and blood homeostasis outside the canonical excision repair pathways

Dear Dr Garaycoechea,

We are pleased to inform you that your manuscript entitled "XPF-ERCC1 protects liver, kidney and blood homeostasis outside the canonical excision repair pathways" has been formally accepted for publication in PLOS Genetics! Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out or your manuscript is a front-matter piece, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Genetics and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Nicholas White

PLOS Genetics

On behalf of:

The PLOS Genetics Team

Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom

plosgenetics@plos.org | +44 (0) 1223-442823

plosgenetics.org | Twitter: @PLOSGenetics

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. Generation of Ercc1-/- mice.

    a) Ercc1+/- crosses in a C57BL/6 background showing that Ercc1-/- mice are genotyped at sub-Mendelian ratios 2–3 weeks after birth (1.9% instead of the expected 25%, Fisher’s exact test: P < 0.0001). b) Ercc1+/- crosses to generate Ercc1-/- mice in a C57BL/6 x 129S6/Sv F1 background. Although Ercc1-/- mice are genotyped at sub-Mendelian ratios 2–3 weeks after birth (12.5% instead of the expected 25%, Fisher’s exact test: P = 0.0002), the mixed genetic background rescues the lethality observed in the C57BL/6 background. c) Survival of Ercc1-/- and control mice in C57BL/6 and C57BL/6 x 129S6/Sv F1 genetic backgrounds.

    (TIF)

    S2 Fig. Generation of HAP1 knock out lines.

    a) Maps of human NER genes. The inset shows the nucleotide and predicted amino acid sequence of wild type and knock out HAP1 lines, generated by introducing deletions with CRISPR/Cas9, see Methods for details. b) Map of the human FANCL gene and targeting of exon 8 to generate isogenic disruptions in FANCL. c) Agarose gel showing disruption of the FANCL locus by long-range PCR. Primers hybridise outside the homology arms and within the targeting construct.

    (TIF)

    S3 Fig. Joint inactivation of TCR and FA crosslink repair does not phenocopy XPF-ERCC1 deficiency.

    a) Crosses for the generation of double mutant mice in a C57BL/6 x 129S6/Sv F1 background, pups were genotyped 2–3 weeks after birth (P: Fisher’s exact test, compared to expected numbers). b) Weights of 8-week-old females in a C57BL/6 x 129S6/Sv F1 background (P: two-tailed Mann-Whitney test, n = 9, 3, 5, 3, 4, 5 and 7). c) Quantification of DNA content in the nuclei of liver cells (P: two-tailed Mann-Whitney test for the frequency of 8n nuclei, n = 6, 5, 5, 5 and 7). d) Serum levels of albumin, alanine transaminase (ALT) and alkaline phosphatase. e) Serum levels of creatinine and urea. f) Quantification of stem and progenitor cells (lineage- c-Kit+ Sca-1+, LKS) and haematopoietic stem cells (LKS CD48- CD150+, HSC) assessed by flow cytometry. In d-f, mice were 8–12 weeks old, C57BL/6 x 129S6/Sv F1 background, error bars represent s.e.m., P: two-tailed Mann-Whitney test. n = 14, 6, 12, 6 and 4.

    (TIF)

    S4 Fig. Model of the interactions between DNA repair pathways that converge on the nuclease XPF-ERCC1.

    a) NER and FA ICL repair interact to protect against certain crosslinkers in vitro and to ensure normal development in a C57BL/6 background. b) XPF-ERCC1 has a role in ICL repair outside NER and ICL unhooking, potentially the repair of DNA double strand breaks (DSBs). c) The XPF-ERCC1 phenotype is likely due to deficiency in NER and non-NER TCR rather than NER and FA ICL repair. How exactly XPF-ERCC1 operates in TCR, and the nature of this damage, remains to be established.

    (TIF)

    S1 Table. gRNAs for the generation of CRISPR knock outs.

    (DOCX)

    S2 Table. Oligos for the screening of CRISPR knock outs by PCR.

    (DOCX)

    S3 Table. Oligos for Sanger sequencing of PCR products.

    (DOCX)

    Attachment

    Submitted filename: Mulderrig - Response to Reviewers.pdf

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files


    Articles from PLoS Genetics are provided here courtesy of PLOS

    RESOURCES